Bhowmick Suvorit S, Desai Soaham D
Movement Disorders Clinic, Vadodara Institute of Neurological Sciences, Vadodara, Gujarat, India.
Neurology Clinic, Sir Sayjirao General Hospital, Vadodara, Gujarat, India.
Ann Indian Acad Neurol. 2025 Jul 1;28(4):495-504. doi: 10.4103/aian.aian_1021_24. Epub 2025 May 7.
By the current estimates, India is likely to face an alarmingly high burden of Parkinson's disease (PD) in the next two decades. Untangling the pathophysiology of PD through genetic research is the key to precision medicine and prevention strategies. This narrative review serves dual purpose of recapitulating phenomenology of monogenic diseases presenting with parkinsonism and synthesizing knowledge on PD genetics gained through research in India over the past two decades. Recent studies have detected rare genetic variants in 15%-20% of the early-onset PD patients in India. Due to lack of segregation analysis and functional validation, a vast majority of these remain as variants of uncertain significance. Nevertheless, several potentially pathogenic variants detected in the Indian PD patients are not yet cited in the global genetic databases such as Movement Disorder Society Genetic mutation database. Biallelic mutations (pathogenic single-nucleotide variants and copy number variants) in the PRKN gene account for 3%-5% of monogenic early-onset PD in the Indian population. About 2%-3% of the Indian EOPD patients carry pathogenic variants in the genes associated with atypical parkinsonism, such as PLA2G6 , suggesting that initially, they may be indistinguishable from monogenic PD. Up to 10% of the PD patients in India carry heterozygous pathogenic variants in GBA1 , a risk factor gene. Genetic research in India has several critical gaps, such as uneven geographic or ethnic representation, discrepancies in variant classification, and lack of large-scale genome-wide association studies. Sustained nationwide as well as international collaborative efforts are needed to bridge these gaps and foster translational science.
据目前估计,印度在未来二十年可能面临帕金森病(PD)令人震惊的高负担。通过基因研究理清PD的病理生理学是精准医学和预防策略的关键。本叙述性综述具有双重目的,即概括呈现帕金森综合征的单基因疾病的现象学,并综合过去二十年来在印度通过研究所获得的关于PD遗传学的知识。最近的研究在印度15%-20%的早发性PD患者中检测到罕见的基因变异。由于缺乏分离分析和功能验证,这些变异中的绝大多数仍为意义未明的变异。然而,在印度PD患者中检测到的几种潜在致病变异尚未在全球遗传数据库如运动障碍协会基因突变数据库中被引用。PRKN基因中的双等位基因突变(致病性单核苷酸变异和拷贝数变异)在印度人群单基因早发性PD中占3%-5%。约2%-3%的印度早发性PD患者在与非典型帕金森综合征相关的基因如PLA2G6中携带致病变异,这表明最初它们可能与单基因PD难以区分。印度高达10%的PD患者在GBA1(一个风险因素基因)中携带杂合致病变异。印度的基因研究存在几个关键差距,如地理或种族代表性不均衡、变异分类存在差异以及缺乏大规模全基因组关联研究。需要持续的全国性以及国际合作努力来弥合这些差距并促进转化科学。